1 day ago · Semaglutide is now approved for reducing the risk for worsening kidney disease and cardiovascular death in adults with chronic kidney disease.

May 24, 2024 · Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease.

2 days ago · The potential of GLP-1 receptor agonists in type 2 diabetes and chronic kidney disease: from randomised trials to clinical practice.

2 days ago · A Phase 3 clinical trial found that injections of the semaglutide medication once weekly reduced the risk of kidney disease worsening by 24% in people who also had diabetes.

3 days ago · The Food and Drug Administration on Tuesday approved Ozempic to reduce the risk of serious complications in people who have both Type 2 diabetes and chronic kidney disease. …

Semaglutide, a glucagon-like peptide-1 receptor agonist is approved for weight loss and diabetes treatment, but limited literature exists regarding semaglutide use in patients with advanced …

Nov 18, 2024 · Its primary outcome was a composite of kidney failure, sustained ≥50% reduction in estimated glomerular filtration rate (eGFR) from baseline, or death from kidney- or …

Nov 30, 2024 · Semaglutide has undeniably emerged as a valuable therapeutic option for managing CKD in patients with type 2 diabetes. Moving forward, research should focus on …

Oct 25, 2024 · Semaglutide reduces albuminuria and the risk of kidney disease progression in patients with type 2 diabetes and chronic kidney disease (CKD).

3 days ago · The new indication for semaglutide adds to the long list of conditions that the GLP-1 receptor agonist has been approved for, and provides a new option for high-risk patients with …